2 November 2020

Kuros Biosciences AG (SIX: KURN) completes a rights offering and share placement in which a total of 10,341,432 new registered shares of Kuros sourced from the ordinary and authorized share capital with a nominal value of CHF 1.00 each were offered or placed, respectively, at an offer price of CHF 1.80 per share. Total gross proceeds raised from the capital increase amount to CHF 18.6m. Kuros intends to use the proceeds of the offering to accelerate and advance the commercial roll-out of its product MagnetOs and to advance the further clinical development of its product candidate Fibrin-PTH.

VISCHER AG advised Kuros Biosciences with Matthias Staehelin (Partner, Corporate), Sebastian Flückiger (Associate, Corporate), Nadia Tarolli (Partner, Tax) and Adrian Briner (Senior Associate, Tax).

Categories: Banking & Finance, Corporate and Commercial, Life Sciences, Pharma, Biotech

You are currently offline. Some pages or content may fail to load.